Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT07778862
What this trial is testing

SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors

Who this might be right for
Gynecological TumorsSolid Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 30
Testing effectiveness (Phase 2)Study completedNCT01466179
What this trial is testing

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH 225
Early research (Phase 1)Active Not RecruitingNCT02609776
What this trial is testing

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Janssen Research & Development, LLC 751
Testing effectiveness (Phase 2)Active Not RecruitingNCT04995523
What this trial is testing

AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Who this might be right for
Non-Small-Cell Lung Carcinoma
AstraZeneca 212
Early research (Phase 1)Study completedNCT04501744
What this trial is testing

M701 (EpCAM and CD3) in Malignant Ascites

Who this might be right for
Malignant AscitesCancer
Wuhan YZY Biopharma Co., Ltd. 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07828522
What this trial is testing

F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Transplant-eligible Patients
Institute of Hematology & Blood Diseases Hospital, China 10
Early research (Phase 1)Looking for participantsNCT05808634
What this trial is testing

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Who this might be right for
Advanced Adenocarcinoma
BioAtla, Inc. 168
Large-scale testing (Phase 3)Looking for participantsNCT05020236
What this trial is testing

Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Who this might be right for
Multiple Myeloma
Pfizer 893
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07685704
What this trial is testing

Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
Zhifeng Zhao, PhD 46
Early research (Phase 1)Ended earlyNCT05638334
What this trial is testing

Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid Tumor
Institut de Recherches Internationales Servier 3
Testing effectiveness (Phase 2)UnknownNCT03146637
What this trial is testing

Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Who this might be right for
Advanced Liver Cancer
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. 80
Testing effectiveness (Phase 2)Study completedNCT01209286
What this trial is testing

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
B-ALL
Amgen Research (Munich) GmbH 36
Testing effectiveness (Phase 2)WithdrawnNCT02521090
What this trial is testing

EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

Who this might be right for
Adult Brain GlioblastomaAdult GliosarcomaRecurrent Brain Neoplasm
Barbara Ann Karmanos Cancer Institute
Early research (Phase 1)Not Yet RecruitingNCT07407010
What this trial is testing

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT05426005
What this trial is testing

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Sun Yat-sen University 28
Early research (Phase 1)UnknownNCT05263180
What this trial is testing

EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Who this might be right for
Advanced Solid Tumor
Shanghai EpimAb Biotherapeutics Co., Ltd. 30
Early research (Phase 1)Ended earlyNCT04740034
What this trial is testing

AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Amgen 42
Early research (Phase 1)Looking for participantsNCT07581704
What this trial is testing

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Christopher Strouse 10
Testing effectiveness (Phase 2)Looking for participantsNCT06642792
What this trial is testing

AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Who this might be right for
Classic Hodgkin Lymphoma
Akeso 280
Early research (Phase 1)Study completedNCT05101109
What this trial is testing

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumor
ABL Bio, Inc. 24
Next Page